Management of neuromuscular dose limiting toxicity at the early stage of drug development.
Faivre
S
S
Raymond
E
E
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D002986:Clinical Trials as Topic; D047630:Depsipeptides / Q000008:administration & dosage / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D015195:Drug Design; D006801:Humans; D020714:Maximum Tolerated Dose; D009369:Neoplasms / Q000188:drug therapy; D009468:Neuromuscular Diseases / Q000139:chemically induced*; D010456:Peptides, Cyclic
D000970:Antineoplastic Agents; D047630:Depsipeptides; D010456:Peptides, Cyclic; C098980:plitidepsin